AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca regulatory approvals in major markets — US, EU, China, Japan (count)
Clinical Trials Appendix (Pipeline at a glance)
Latest, Q2 2026
15
Period ended Jun 30, 2026
Change on a year earlier
+87.5%
8 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Regulatory approvals in major markets — US, EU, China, Japan (count) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 15 | +87.5% | Clinical Trials Appendix (2026Q2) ↗ |
| Q1 2026 | Mar 31, 2026 | 14 | -12.5% | Clinical Trials Appendix (2026Q1) ↗ |
| Q4 2025 | Dec 31, 2025 | 7 | +16.7% | Clinical Trials Appendix (2025Q4) ↗ |
| Q3 2025 | Sep 30, 2025 | 12 | +33.3% | Clinical Trials Appendix (2025Q3) ↗ |
| Q2 2025 | Jun 30, 2025 | 8 | +14.3% | Clinical Trials Appendix (2025Q2) ↗ |
| Q1 2025 | Mar 31, 2025 | 16 | +77.8% | Clinical Trials Appendix (2025Q1) ↗ |
| Q4 2024 | Dec 31, 2024 | 6 | – | Clinical Trials Appendix (2024Q4) ↗ |
| Q3 2024 | Sep 30, 2024 | 9 | – | Clinical Trials Appendix (2024Q3) ↗ |
| Q2 2024 | Jun 30, 2024 | 7 | – | Clinical Trials Appendix (2024Q2) ↗ |
| Q1 2024 | Mar 31, 2024 | 9 | – | Clinical Trials Appendix (2024Q1) ↗ |
Cite this data
StockData. (2026). AstraZeneca Regulatory approvals in major markets — US, EU, China, Japan (count), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/cta_reg_approvals
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.